DarioFabianMirskiMD

Psychiatry • Nokomis, FL

Geriatric Psychiatry

Sr VP Clinical Development

Join to view full profile

Dr. Mirski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mirski's full profile

Already have an account?

Office
office
Nokomis, FL 34275

Education & Training

Medical University of South CarolinaResidency, Psychiatry, 1996 - 1998
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Psychiatry, 1993 - 1996
University of Buenos AiresClass of 1989

Certifications & Licensure

FL State Medical License 1999 - 2027
NY State Medical License 1996 - 2025
SC State Medical License 1996 - 2025
American Board of Psychiatry and Neurology Psychiatry

Publications & Presentations

PubMed

3 citations
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial.
Pepijn Eijsvogel, Pinaki Misra, Luis Concha-Marambio, Justin D Boyd, Shuang Ding
Nature Medicine. 2024-09-01
20 citations
Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage.
Steve Offord, Jay Lin, Bruce Wong, Dario Mirski, Ross A. Baker
Community Mental Health Journal. 2013-08-10
41 citations
Healthcare Cost Reductions Associated with the Use of LAI Formulations of Antipsychotic Medications Versus Oral Among Patients with Schizophrenia
Jay Lin, Bruce Wong, Steve Offord, Dario Mirski
The Journal of Behavioral Health Services & Research. 2013-04-12

Press Mentions

FDA Approves Bayer’s Kyleena IUDSeptember 20th, 2016
FDA Approves Bayer's Kyleena™ (Levonorgestrel-Releasing Intrauterine System) 19.5 Mg for Prevention of Pregnancy for up to Five YearsSeptember 19th, 2016
Bayer to Highlight Latest Stivarga® (Regorafenib) Tablets Research at ASCO GI 2016January 19th, 2016